PBAC's latest decision on Citrulline: Recommended (2015). Considered for Treatment of urea cycle disorders, specifically for preventing low plasma arginine or citrulline levels.
PBAC outcome
Recommended
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2015
Submissions
1
2015 → 2015
Eligible population
Patients with urea cycle disorders requiring citrulline supplementation.
Therapy area
Metabolic
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
Citrulline 1000® powder sachets
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; nil cost to PBS estimated due to direct substitution at equivalent price per gram of citrulline.